Action ZNTL ZENTALIS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zentalis Pharmaceuticals, Inc.

Actions

ZNTL

US98943L1070

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 17/05/2024 		Varia. 5j. Varia. 1 janv.
12,07 USD +0,92 % Graphique intraday de Zentalis Pharmaceuticals, Inc. -3,75 % -20,33 %
08/05 ZENTALIS PHARMACEUTICALS, INC. : Stifel Nicolaus optimiste sur le dossier ZM
07/05 Zentalis Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals, Inc. Announces Executive Changes
Zentalis Pharmaceuticals, Inc. Announces CFO Changes
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Zentalis Pharmaceuticals, Inc. Announces Executive Changes
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ZNTL
  4. Actualités Zentalis Pharmaceuticals, Inc.
  5. Autres langues